Belimumab deemed safe for long-term lupus treatment

June 19, 2012
Belimumab deemed safe for long-Term lupus treatment
For patients with systemic lupus erythematosus, long-term belimumab therapy combined with standard therapy is well tolerated, according to a study published online June 5 in Arthritis & Rheumatism.

(HealthDay) -- For patients with systemic lupus erythematosus (SLE), long-term belimumab therapy combined with standard therapy is well tolerated, according to a study published online June 5 in Arthritis & Rheumatism.

Joan T. Merrill, M.D., from the Oklahoma Medical Research Foundation in Oklahoma City, and colleagues evaluated the long-term safety profile of belimumab for with active SLE. Patients who were randomized to 1, 4, or 10 mg/kg belimumab or placebo and completed a 52-week double-blind study were eligible for a 24-week extension (345 patients). Placebo patients were switched to 10 mg/kg belimumab and belimumab patients continued with their dose or were switched to 10 mg/kg. Two hundred ninety-six participants who achieved a satisfactory response were allowed to continue in the long-term evaluation of monthly 10 mg/kg belimumab.

The researchers found that, during four-year belimumab exposure, the incidence rates of adverse events (AEs), severe/serious AEs, infusion reactions, infections, malignancies, grades 3/4 laboratory abnormalities, and AE-related discontinuations remained stable or decreased. Arthralgia, upper respiratory tract infection, headache, fatigue, and nausea were the most common AEs. Only one serious infusion reaction occurred during the four-year follow-up. No specific infection type dominated the AEs and serious infection rates decreased from 5.9 to 3.4/100 patient-years.

"Belimumab added to standard therapy was generally well tolerated over four-year treatment for SLE, suggesting that belimumab can be administered long term with an acceptable safety profile," the authors write.

Several authors disclosed financial ties to Human Genome Sciences Inc. and GlaxoSmithKline, both of which funded the study and manufacture belimumab.

Explore further: Etanercept shows promise for treating dermatomyositis

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Etanercept shows promise for treating dermatomyositis

June 17, 2011

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy. These results are encouraging, ...

Chemo combination promising for multiple myeloma

May 2, 2012

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

Recommended for you

Team finds gene that confirms existence of psoriatic arthritis

February 5, 2015

PsA is a common form of inflammatory form of arthritis causing pain and stiffness in joints and tendons that can lead to joint damage. Nearly all patients with PsA also have skin psoriasis and, in many cases, the skin disease ...

Blocking one receptor could halt rheumatoid arthritis

September 10, 2014

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis—and that activation ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.